Sana Biotechnology Inc

Item 5. Other Information

(a)

(b)

(c)

During our last fiscal quarter, the following officer, as defined in Rule 16a-1(f), adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408, as follows:

On March 5, 2024, Nathan Hardy, our Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 76,125 shares of our common stock and aggregate of up to 23,813 shares of common stock issuable upon the exercise of options. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until March 15, 2026, or earlier if all transactions under the trading arrangement are completed. On March 13, 2024, Mr. Hardy terminated a separate Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 140,236 shares of our common stock and an aggregate of up to 76,692 shares of common stock issuable upon the exercise of options. The trading arrangement was intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement was until April 20, 2024, or earlier if all transactions under the trading arrangement were completed.

No other officers or directors, as defined in Rule 16a-1(f), adopted and/orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the last fiscal quarter.